PubMed Health⌕ Search

Biomedical subjects

C Bakker

Publications and source records attributed to C Bakker.

22 records · Page 2Linked to original sources
PubMed1993

Measures to assess ankylosing spondylitis: taxonomy, review and recommendations.

OBJECTIVE: To critically review the current use and scope of measures to assess patients with ankylosing spondylitis (AS). METHODS: Studies in English reported between January, 1986 and August, 1991 were identified both through computer searches of Index Medicus and manual searches of bibliographies. Only studies where assessment of patients with AS was a main topic were included. Information was extracted to classify measures as (1) physician assessed, (2) patient reported or (3) other assessments. RESULTS: Physician assessed measures prevailed in 34 (79%) of the 43 studies included. Patient reported measures were mentioned in 29 (67%). Most physician assessed measures (67%) focussed on mobility, most patient reported measures (65%) focussed on discomfort. Single item global assessment by physician or patient, the most generic measure, was reported in 7 (16%) and in 17 (40%) studies, respectively. One study reported a measure which specifically addressed the patient's priorities regarding treatment risks. Other measures were reported in 22 (51%) studies, i.e., laboratory tests in all 22, and additionally radiographs in 2, and various measures in 6 studies. Side effects (by reports or otherwise) were noted in 26 (60%) studies. CONCLUSION: Current assessment in AS incompletely encompasses the spectrum of relevant health status outcomes. Specifically, more attention should be paid to the patient's point of view.

Classification↗
PubMed1992

Characterization of soluble protein BCP 11/24 from bovine corneal epithelium, different from the principal soluble protein BCP 54.

The water-soluble fraction of bovine corneal epithelium was analysed by polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE). Next to the principal soluble protein BCP 54, which has recently been identified as a corneal aldehyde dehydrogenase (ALDH), another abundant protein was observed, which we have denoted BCP 11/24, due to its estimated molecular weight of 11 kDa in SDS-PAGE and 24 kDa in high performance gel filtration under non-denaturing conditions. This protein was isolated and characterized by biochemical and immunochemical techniques. The isolation of BCP 11/24 was initially hampered by its tendency to bind non-covalently to BCP 54. BCP 11/24 behaves identically in reduced and unreduced SDS-PAGE and is probably not a glycoprotein. Isoelectric focusing indicated microheterogeneity of BCP 11/24, yielding bands with isoelectric points of 6.1, 5.9, 5.7 and 5.6. A rabbit antiserum directed against BCP 11/24, that did not recognize BCP 54, demonstrated that the distribution of BCP 11/24 in different ocular tissues as well as its light microscopic localization in corneal epithelium is strikingly similar to that of BCP 54. Together with its tendency to interact with BCP 54 in vitro, this suggests the possibility that BCP 11/24 is associated with BCP 54 in vivo, fulfilling a function which may be related to the activity of BCP 54 as a corneal ALDH. In contrast with BCP 54, however, BCP 11/24 was not detectable in corneal endothelium. The antiserum did not detect any immunologically related molecules in corneal epithelium extracts of sheep, human or rat origin, indicating that BCP 11/24 is probably not as highly conserved as BCP 54.

Aldehyde Dehydrogenase↗
PubMed1987

Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam.

An experimental model was developed to elucidate the site of presystemic extraction of drugs with incomplete bioavailability due to high extraction after p.o. dosage. Domestic pigs received single i.v. or p.o. doses of midazolam (1 mg/kg) or flurazepam (2 mg/kg), two benzodiazepine derivatives with high presystemic extraction after p.o. dosage. Multiple blood samples were simultaneously drawn from the portal vein and from a systemic vein during 8 hr after dosage. After i.v. administration, both drugs had high systemic serum clearance, averaging 24 ml/min/kg. Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01). After p.o. dosage, the systemic/portal AUC ratio averaged 0.15 for midazolam and 0.11 for flurazepam; for both drugs, portal AUC after p.o. dosage did not differ significantly from systemic AUC after i.v. administration. Thus, the extensive presystemic extraction of orally administered midazolam and flurazepam are mainly attributable to hepatic biotransformation rather than metabolism either within the gastrointestinal tract or during absorption into the portal circulation.

Administration, Oral↗